UniProtKB/Swiss-Prot P23945: Variant p.Thr449Ile

Follicle-stimulating hormone receptor
Gene: FSHR
Chromosomal location: 2p16-p21
Variant information

Variant position:  449
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Threonine (T) to Isoleucine (I) at position 449 (T449I, p.Thr449Ile).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to medium size and hydrophobic (I)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In OHSS.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  449
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  695
The length of the canonical sequence.

Location on the sequence:   YHNYAIDWQTGAGCDAAGFF  T VFASELSVYTLTAITLERWH
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWH

Mouse                         YHNYAIDWQTGAGCDAAGFFTVFASELSVYTLAAITLERWH

Rat                           YHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWH

Pig                           YHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWH

Bovine                        YHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWH

Sheep                         YHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWH

Cat                           YHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTVITLERWH

Horse                         YHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWH

Chicken                       YYNYAIDWQTGAGCNAAGFFTVFASELSVYTLTVITLERWH

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 18 – 695 Follicle-stimulating hormone receptor
Transmembrane 444 – 465 Helical; Name=3
Disulfide bond 442 – 517


Literature citations

A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome.
Vasseur C.; Rodien P.; Beau I.; Desroches A.; Gerard C.; de Poncheville L.; Chaplot S.; Savagner F.; Croue A.; Mathieu E.; Lahlou N.; Descamps P.; Misrahi M.;
N. Engl. J. Med. 349:753-759(2003)
Cited for: VARIANT OHSS ILE-449;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.